A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Reference |
|---|
| "Hyperphosphatemia is one of the more prevalent metabolic disturbances in kidney failure." | ( Burke, SK, 2008) |
| "Hyperphosphatemia is independently associated with an increased risk of death among dialysis patients." | ( Akçiçek, F; Akpolat, T; Arinsoy, T; Ataman, R; Ateş, K; Bozfakioğlu, S; Camsari, T; Dimitriades, AC; Dombros, NA; Ersoy, FF; Evaggelos, DM; Gültekin, M; Karayaylali, I; Katopodis, KP; Oreopoulos, DG; Ozener, C; Passadakis, PS; Stathakis, CP; Süleymanlar, G; Tam, P; Tsakiris, DJ; Utaş, C; Vlachojannis, GJ; Wu, G; Yavuz, A; Yavuz, M; Yilmaz, ME, 2008) |
| "Hyperphosphatemia is highly prevalent in dialysis patients and may be associated with immune dysfunction." | ( Briggs, WA; Fink, NE; Jaar, BG; Melamed, ML; Plantinga, LC; Powe, NR, 2008) |
| "Hyperphosphatemia is an independent risk factor for mortality in ESRD, but factors regulating phosphate clearance on peritoneal dialysis (PD) are incompletely understood." | ( Badve, SV; Burns, KD; Knoll, GA; McCormick, BB; Zimmerman, DL, 2008) |
| "Hyperphosphatemia is a complication that appears in the early stages of chronic kidney disease (CKD) and that has been shown to have serious consequences in kidney disease patients." | ( Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM, 2008) |
| "In uremic patients, hyperphosphatemia is associated with cardiovascular calcification and increased cardiovascular mortality." | ( Bellinghieri, G; Calò, LA; Comelli, MC; Davis, PA; Granata, A; Monardo, P; Musolino, R; Santoro, D; Savica, R; Savica, V, 2009) |
| "Hyperphosphatemia is an important modifiable risk factor in the dialysis population because it is linked to increased mortality." | ( Sampathkumar, K, 2009) |
| "Hyperphosphatemia is treated by dietary limitation of phosphorus ingestion and by phosphate binders, but only half of ESRD patients fall within the range of K/DOQI guidelines." | ( Bellinghieri, G; Calò, LA; Mallamace, A; Monardo, P; Muraca, U; Santoro, D; Savica, V, 2009) |
| "Hyperphosphatemia is associated with an increased risk of cardiovascular morbidity and mortality." | ( Guidi, GC; Lippi, G; Montagnana, M; Salvagno, GL; Targher, G, 2009) |
| "Hyperphosphatemia is an almost universal finding in patients with end-stage renal disease and is associated with increased all-cause mortality, cardiovascular mortality, and vascular calcification." | ( Tanaka, M, 2009) |
| "Hyperphosphatemia is a major problem in these patients with advanced stage of CKD." | ( Yokoyama, K, 2009) |
| "Since hyperphosphatemia is an established risk factor for not only secondary hyperparathyroidism, but also cardiovascular mortality in these patients, the adequate control of serum phosphorus is necessary." | ( Akizawa, T; Mizobuchi, M; Sanada, D, 2009) |
| "Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism." | ( Barton Pai, A; Conner, TA; McQuade, CR, 2009) |
| "Hyperphosphatemia is an inevitable consequence of end-stage chronic kidney disease and is present in the majority of dialysis patients." | ( Hutchison, AJ, 2009) |
| "Hyperphosphatemia is currently regarded as a key mortality risk predictor in late CKD stages and especially in patients on dialysis." | ( Ketteler, M, 2009) |
| "Hyperphosphatemia is highly prevalent in patients with chronic kidney disease (CKD), particularly in those with advanced or end-stage renal disease." | ( Pai, AB; Shepler, BM, 2009) |
| "Hyperphosphatemia is one of the key risk factors for aortic valve calcification." | ( Obrenović, R; Petrović, D; Stojimirović, B, 2009) |
| "Hyperphosphatemia is an independent risk factor for aortic valve calcification." | ( Obrenović, R; Petrović, D; Stojimirović, B, 2009) |
| "Hyperphosphatemia is a central characteristic feature of chronic kidney disease-mineral and bone disorder (CKD-MBD)." | ( Brandenburg, VM; Jahnen-Dechent, W; Ketteler, M, 2009) |
| "Hyperphosphatemia is a cardiovascular risk factor in patients with chronic kidney disease." | ( Arnlöv, J; Hagström, E; Ingelsson, E; Larsson, TE; Lind, L; Olauson, H; Sundström, J, 2010) |
| "Hyperphosphatemia is an independent risk factor for all-cause and cardiovascular mortality in hemodialysis (HD) patients." | ( Blankestijn, PJ; Bots, ML; Grooteman, MP; Lévesque, R; Nubé, MJ; Penne, EL; ter Wee, PM; van den Dorpel, MA; van der Weerd, NC, 2010) |
| "Hyperphosphatemia is common among patients receiving dialysis and is associated with increased mortality." | ( Culleton, B; Hemmelgarn, B; Klarenbach, S; Manns, BJ; Tonelli, M; Walsh, M, 2010) |
| "Although hyperphosphatemia is believed to be a risk factor for mortality and VC, no randomized trial was ever designed to demonstrate that lowering phosphate reduces mortality." | ( Moysés, RM; Raggi, P; Spiegel, DM; Vukicevic, S; Wesseling, K, 2010) |
| "Hyperphosphatemia is highly prevalent in hemodialysis (HD) and peritoneal dialysis (PD) patients and is a major risk factor for cardiovascular mortality." | ( Kuhlmann, MK, 2010) |
| "Hyperphosphatemia is associated with higher mortality and increased incidence of end-stage renal disease in patients with non-dialysis dependent CKD (NDD-CKD), but there has not been a concomitant assessment of mortality and progressive kidney disease that would also account for cumulative effects of hyperphosphatemia." | ( Anderson, JE; Kalantar-Zadeh, K; Kovesdy, CP, 2010) |
| "Hyperphosphatemia is a serious complication which has been linked with an increased risk of cardiovascular mortality in patients with chronic kidney disease." | ( Negi, S; Shigematsu, T, 2010) |
| "Hyperphosphatemia is not an expected consequence of dosing with amphotericin B formulations." | ( Bunch, TH; Jensen, GM; Laybourne, S; Wolf, S, 2010) |
| "Hyperphosphatemia is common among hemodialysis patients." | ( Brunelli, SM; Curhan, GC; Lynch, KE; Lynch, R, 2011) |
| "In uremic patients, hyperphosphatemia is associated with cardiovascular calcification and increased cardiovascular mortality." | ( Bellinghieri, G; Calò, LA; Davis, PA; Monardo, P; Muraca, U; Santoro, D; Santoro, G; Savica, V, 2011) |
| "Hyperphosphatemia is a well-recognized complication of chronic kidney disease, and phosphorus kinetics during hemodialysis (HD) remains a vague area of investigation." | ( Challa, AS; Dounousi, EC; Karasavvidou, DP; Katopodis, KP; Vlachou, IA, 2011) |
| "Hyperphosphatemia is the strongest independent risk factor for mortality in renal patients." | ( Brunner-Ziegler, S; Fröschl, B; Hiebinger, C; Zsifkovits, J, 2011) |
| "Because hyperphosphatemia is a major consequence of renal impairment, this study determines the in vivo effects of hyperphosphatemia in obesity." | ( Kato, S; Ohnishi, M; Razzaque, MS, 2011) |
| "Hyperphosphatemia is a common and potentially harmful condition in patients with end-stage kidney disease." | ( Keith, MS; Lok, CE; Morton, AR; Soroka, SD; Tolley, K; Vegter, S, 2012) |
| "Hyperphosphatemia is a serious complication which has been linked with an increased risk of cardiovascular mortality in patients with chronic kidney disease." | ( Hanba, Y; Masumoto, A; Moribata, M; Shigemathu, T, 2012) |
| "The control of hyperphosphatemia is an unmet need in dialysis care." | ( Dorigo, DM; Ruzany, F; Sampaio, MS; Suassuna, JH, 2012) |
| "Hyperphosphatemia is an infrequent, but potentially life-threatening complication of laxative application." | ( Deluggi, S; Ladenhauf, HN; Spreitzhofer, F; Stundner, O, 2012) |
| "Hyperphosphatemia is a significant risk factor for the development of ectopic calcification and coronary artery diseases in patients on hemodialysis (HD), and must be controlled with the use of phosphate binders." | ( Ahmadi, F; Khatami, MR; Lessan-Pezeshki, M; Shamekhi, F, 2012) |
| "The issue of hyperphosphatemia is prominent and needs further attention." | ( Chen, J; Chen, N; Chen, W; Chen, X; Ding, F; Fan, M; Gu, Y; He, L; Hou, F; Jia, Q; Kong, X; Liu, W; Mei, C; Ni, Z; Peng, L; Shi, W; Shu, G; Tang, X; Wang, H; Wang, L; Wang, M; Wu, H; Xing, C; Xiong, Z; Xu, D; Yu, X; Yuan, W; Zhang, J; Zhang, L; Zuo, L, 2012) |
| "Hyperphosphatemia is the most common complication among patients with chronic kidney disease." | ( Koreeda, D; Negi, S; Shigematsu, T; Yamanaka, S; Yashiro, M, 2012) |
| "Treatment of hyperphosphatemia is important in patients with CKD." | ( Hamada, Y; Usami, M, 2012) |
| "Hyperphosphatemia is a common disorder in patients with chronic kidney disease (CKD) , and may result in hyperparathyroidism and renal osteodystrophy." | ( Kido, S; Nomura, K; Sasaki, S; Segawa, H; Shiozaki, Y; Tatsumi, S, 2012) |
| "Hyperphosphatemia is a common complication in end-stage renal disease (ESRD) patients." | ( Choi, HY; Lee, HY; Lee, YK; Shin, SK, 2013) |
| "Hyperphosphatemia is a paradigmatic finding in late-stage chronic kidney disease (CKD) and consistently associated with adverse outcomes." | ( Biggar, PH; Ketteler, M, 2013) |
| "Hyperphosphatemia is associated with cardiovascular disease in patients with chronic kidney disease." | ( Akizawa, T; Kinugasa, E; Koiwa, F; Kondo, F; Kumata, C; Mizobuchi, M; Ogata, H; Ono, N; Uda, S; Yamazaki-Nakazawa, A, 2014) |
| "Hyperphosphatemia is a nearly universal complication of end-stage renal disease that is widely recognized as one of the most important and most challenging clinical targets to meet in the care of dialysis patients." | ( Isakova, T; Lenz, O; Pedraza, F; Waheed, AA, 2013) |
| "Hyperphosphatemia is one of the major factors associated with the development of vascular calcification in patients with chronic kidney disease (CKD)." | ( Goumenos, DS; Papachristou, E; Sonikian, M, 2013) |
| "Hyperphosphatemia is an important determinant of morbidity and mortality in patients with chronic kidney disease (CKD)." | ( Kitajima, M; Razzaque, MS; Saitoh, H; Saitoh, Y; Shimada, M; Shutto, Y; Yamabe, H, 2013) |
| "Hyperphosphatemia is a serious complication of late-stage chronic kidney disease (CKD), contributing to the increased cardiovascular morbidity and mortality seen in this patient group." | ( Lee, GJ; Marks, J, 2015) |
| "Hyperphosphatemia is common in the late stages of chronic kidney disease (CKD) and is associated with elevated parathormone levels, abnormal bone mineralization, extraosseous calcification and increased risk of cardiovascular events and death." | ( Del Vecchio, L; Locatelli, F; Pontoriero, G; Violo, L, 2014) |
| "Hyperphosphatemia is a prognostic factor for morbidity and mortality in chronic kidney disease." | ( Akizawa, T; Kameoka, C; Kaneko, Y; Kawasaki, S; Origasa, H, 2014) |
| "Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders." | ( Chiang, SS; Lee, CT; Peng, YS; Shu, KH; Wu, IW; Wu, MJ; Wu, MS, 2015) |
| "Hyperphosphatemia is a prognostic factor for morbidity and mortality in chronic kidney disease." | ( Akizawa, T; Kameoka, C; Kaneko, Y; Kanoh, H; Origasa, H, 2014) |
| "Hyperphosphatemia is a major problem in these patients especially at advanced stages of CKD, and it is associated with cardiovascular and mineral complications in these patients." | ( Maizel, J; Massy, ZA, 2014) |
| "Hyperphosphatemia is strongly associated with cardiovascular morbidity and mortality in patients with chronic kidney disease." | ( Bosomworth, M; Costelloe, S; Fouque, D; Freeman, J; Keane, D; Lindley, E; Thompson, D, 2014) |
| "Nonetheless, hyperphosphatemia is a late marker of phosphate overload in humans." | ( Cozzolino, M; Cupisti, A; Galassi, A; Santoro, A, 2015) |
| "Spurious hyperphosphatemia is a relatively common phenomenon in patients with monoclonal gammopathy which can compromise patient safety." | ( Chakraborty, S; Kallner, A, 2015) |
| "Hyperphosphatemia is linked to the catabolic profile but the effect of renal impairment can't be ruled out." | ( Anker, SD; Doehner, W; Hudzik, B; Jankowska, EA; Kawecka, E; Kokocińska, D; Myrda, K; Niedziela, J; Nowak, J; Partyka, R; Poloński, L; Ponikowski, P; Rozentryt, P; Rywik, T; Szyguła, B; von Haehling, S, 2014) |
| "Hyperphosphatemia is an independent risk factor of cardiovascular events in the patients with chronic kidney disease." | ( Deng, B; Mohan, C; Peng, A; Qin, L; Tang, B; Wu, T, 2015) |
| "Hyperphosphatemia is common in end-stage renal disease and associates with mortality." | ( Browne, T; Cavanaugh, K; Ikizler, TA; Lewis, JB; Merighi, JR; Umanath, K; Umeukeje, EM; Victoroff, JN; Wallston, KA, 2015) |
| "Hyperphosphatemia is known to adversely affect mortality and quality of life in chronic kidney disease patients and has been shown to be involved not only in the onset and progression of secondary hyperparathyroidism but also in vascular calcification." | ( Iwatani, Y; Masumoto, AR; Mima, T; Moribata, MK; Nakashima, YM; Negi, S; Ohya, M; Shigematsu, T; Tatsuta, K; Yamanaka, S, 2015) |
| "Hyperphosphatemia is the most common metabolic complications of end-stage kidney disease (ESKD)." | ( Amiri, FS, 2015) |
| "Hyperphosphatemia is an independent predictor for cardiovascular and all-cause mortality in patients undergoing peritoneal dialysis (PD)." | ( Fang, W; Gu, AP; Jiang, N; Lin, AW; Ni, ZH; Qian, JQ; Yang, XX; Yuan, JZ, 2015) |
| "Hyperphosphatemia is an independent risk factor for CAC progression, and the serum phosphate level may be associated with protein intake and PD adequacy." | ( Ge, X; Hao, CM; Kuang, D; Shang, D; Tian, J; Xie, Q; Yan, H; Zhu, T, 2015) |
| "Hyperphosphatemia is a frequent complication of chronic kidney disease and is associated with increased mortality." | ( Lederer, SR; Schmid, H, 2015) |
| "Hyperphosphatemia is a common problem in patients with end-stage renal disease (ESRD) who are on maintenance hemodialysis (HD) and contributes to the development of secondary hyperparathyroidism and cardiovascular complications." | ( El Borolossy, R; El Hakim, I; El Wakeel, LM; Sabri, N, 2016) |
| "Hyperphosphatemia is thought to be a central-risk factor for CKD-MBD." | ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| "Hyperphosphatemia is associated with accelerated vascular endothelial dysfunction in patients with chronic kidney disease (CKD)." | ( Kang, X; Liu, JY; Mohan, C; Peng, A; Tang, B; Wu, T; Zhou, R, 2016) |
| "Hyperphosphatemia is common in chronic kidney disease (CKD) and is treated by dietary measures, dialysis techniques and/or phosphate binders." | ( Floege, J, 2016) |
| "Hyperphosphatemia is common in chronic kidney disease (CKD) and associated with mortality and morbidity." | ( Koiwa, F; Terao, A, 2017) |
| "Hyperphosphatemia is a hallmark of advanced chronic kidney disease (CKD) and associated with adverse outcomes." | ( Biggar, PH; Ketteler, M; Liangos, O, 2016) |
| "Hyperphosphatemia is associated with higher risk for cardiovascular mortality and morbidity along a gradient beginning at 5." | ( Copland, M; Komenda, P; McCullough, PA; Morfin, JA; Weinhandl, ED, 2016) |
| "Hyperphosphatemia is associated with all-cause mortality in hemodialysis (HD) patients and is managed by restricting dietary phosphate." | ( Adams, MA; Christilaw, E; Holden, RM; Lynch, SK; Nelson, SM; Sarabia, SR; Ward, EC, 2017) |
| "Hyperphosphatemia is common among patients with CKD stage 5D and is associated with morbidity and mortality." | ( Åstrand, M; Block, GA; Chertow, GM; Johansson, S; Knutsson, M; Langkilde, AM; Leonsson-Zachrisson, M; Rosenbaum, DP, 2017) |
| "Hyperphosphatemia is common in patients with chronic kidney disease (CKD) stages IV and V because of decreased phosphorus excretion." | ( Araujo, RM; Barretti, P; Caramori, JCT; Vogt, BP; Watanabe, MT, 2016) |
| "Hyperphosphatemia is common among recipients of maintenance dialysis and is associated with a higher risk of mortality and cardiovascular events." | ( Bosch, J; Gao, P; Garg, AX; Girard, L; Manns, BJ; Mazzetti, A; Parfrey, P; Rabbat, CG; Rathe-Skafel, A; Smyth, A; Tennankore, K; Tyrwhitt, J; Wald, R; Walsh, M; Yan, AT, 2017) |
| "Mild hyperphosphatemia is a putative risk factor for cardiovascular disease [CVD], loss of kidney function, and mortality." | ( Bostom, A; Carpenter, MA; Foster, MC; Gohh, R; House, AA; Ix, JH; Jacques, P; Kew, CE; Kim, SJ; Kusek, JW; Levey, AS; Merhi, B; Pesavento, TE; Pfeffer, M; Rao, M; Shireman, T; Smith, SR; Weiner, DE, 2017) |
| "Hyperphosphatemia is a late complication of chronic kidney disease (CKD)." | ( Bouajila, IA; De Seigneux, S; Martin, PY, 2017) |
| "Hyperphosphatemia is related to some pathologies, affecting vascular cell behavior." | ( Alcalde-Estevez, E; López-Ongil, S; Martínez-Miguel, P; Medrano, D; Naves-Diaz, M; Olmos, G; Rodríguez-Mañas, L; Rodríguez-Puyol, D; Ruiz-Torres, MP; Sosa, P, 2017) |
| "Hyperphosphatemia is one of the most notable features of chronic kidney disease (CKD)." | ( Bi, X; Huang, Y; Jiang, W; Liu, Y; Xiao, T; Xiong, J; Xu, X; Yu, Y; Zhang, B; Zhang, D; Zhang, J; Zhao, J, 2017) |
| "Hyperphosphatemia is associated with high mortality rate in patients on dialysis." | ( Alvares, VRC; Elias, RM; Moysés, RMA, 2018) |
| "Hyperphosphatemia is associated with mortality in patients with chronic kidney disease, and is common in critically ill patients with acute kidney injury (AKI); however, its clinical implication in these patients is unknown." | ( Chang, TI; Han, SH; Jhee, JH; Jung, SY; Kang, EW; Kang, SW; Kee, YK; Kim, H; Kwon, J; Park, JT; Park, S; Yoo, TH; Yoon, CY; Yun, HR, 2018) |
| "Hypo- and hyperphosphatemia are common in severe sepsis and septic shock." | ( Doepker, BA; Exline, MC; Miller, CJ; Murphy, CV; Phillips, G; Springer, AN, 2020) |
| "It is known that hyperphosphatemia is associated with coronary artery calcification." | ( Fujii, H; Hamano, T; Isaka, Y; Teramukai, S; Tsujimoto, Y, 2018) |
| "Hyperphosphatemia is common in patients on hemodialysis." | ( Li, H; Lu, X; Wang, F; Wang, S; Xiong, R; Zhang, J, 2018) |
| "Hyperphosphatemia is common in late stages of chronic kidney disease and is often associated with elevated parathormone levels, abnormal bone mineralization, extra-osseous calcification, and increased risk of cardiovascular events and death." | ( Carfagna, F; Del Vecchio, L; Locatelli, F; Pontoriero, G, 2018) |
| "Hyperphosphatemia is a common complication in patients with end-stage renal disease on hemodialysis." | ( Brauer, A; Maursetter, L; Singh, T; Waheed, S, 2019) |
| "Hyperphosphatemia is considered a decisive determinant of vascular calcification in CKD." | ( Alesutan, I; Amann, K; Eckardt, KU; Kuro-O, M; Lang, F; Pasch, A; Pieske, B; Voelkl, J, 2019) |
| "Hyperphosphatemia is a major risk factor leading to morbidity and mortality in patients with chronic kidney disease." | ( Han, M; Li, J; Li, Y; Liao, R; Maharjan, A; Su, B; Sun, S; Wang, L; Xiong, Y, 2019) |
| "Hyperphosphatemia is associated with increased risk for chronic kidney disease (CKD) progression and reduced antiproteinuric effects of renin-angiotensin system (RAS) blockers." | ( Aparicio, C; Bellasi, A; Cannata, A; Cozzolino, M; Ferrari, S; Kohan, DE; Lecchi, V; Mallamaci, F; Mazzaferro, S; Peraro, F; Perna, A; Perticucci, E; Remuzzi, G; Rotondi, S; Ruggenenti, P; Ruggiero, B; Tartaglione, L; Trillini, M; Tripepi, R; Villa, D; Zoccali, C, 2019) |
| "Background Hyperphosphatemia is a common consequence in end stage renal disease." | ( Chan, MW; Cheah, HM; Mohd Padzil, MB, 2019) |
| "Hyperphosphatemia is associated with vascular calcification and bone mineral disorders and is a major concern among patients with chronic kidney disease (CKD)." | ( Chin, HJ; Han, SS; Joo, KW; Kim, S; Kim, YS; Moon, H; Na, KY, 2019) |
| "Hyperphosphatemia is related to the risks of AKI, ESRD, and mortality, and it may therefore be necessary to monitor serum phosphorus level in hospitalized patients, irrespective of kidney function." | ( Chin, HJ; Han, SS; Joo, KW; Kim, S; Kim, YS; Moon, H; Na, KY, 2019) |
| "Hyperphosphatemia is a secondary issue associated with chronic kidney disorder." | ( Anand, A; Aoyagi, H, 2019) |
| "Hyperphosphatemia is a mineral bone-disease that increases cardiovascular complications and all-cause mortality in chronic kidney disease (CKD) patients." | ( Abediazar, S; Ardalan, M; Bahmanpoor, Z; Hosseiniyan Khatibi, SM; Majdi, H; Niknafs, B; Rahbar Saadat, Y; Zununi Vahed, S, 2020) |
| "The control of hyperphosphatemia is key to the management of chronic kidney disease mineral and bone disorder." | ( Bowles, M; Byrne, FN; Connolly, P; Earlie, J; Eustace, J; Gillman, B; Kearney, P; Kiely, M; Murphy, J; Reilly, EO; Rennick, T; Shiely, F, 2021) |
| "Hyperphosphatemia is associated with increased fibroblast growth factor 23 (FGF23), arterial calcification, and cardiovascular mortality." | ( Badve, SV; Block, GA; Boudville, N; Cameron, JD; Campbell, KL; Chen, SSM; Elder, GJ; Faull, RJ; Hawley, CM; Holt, SG; Hooi, LS; Jackson, D; Jardine, MJ; Johnson, DW; Kerr, PG; Lau, KK; Lioufas, NM; Narayan, O; Pascoe, EM; Pedagogos, E; Perkovic, V; Polkinghorne, KR; Pollock, CA; Reidlinger, D; Robison, L; Smith, ER; Toussaint, ND; Valks, A; Walker, RJ; Wang, AYM, 2020) |
| "Hyperphosphatemia is a risk factor for poor clinical outcomes in patients with kidney failure receiving maintenance dialysis." | ( Beddhu, S; Brosch, R; Brunelli, S; Chakraborty, H; Dember, LM; Edmonston, DL; Isakova, T; Wolf, M; Young, A, 2021) |
| "Hyperphosphatemia is a persistent problem in individuals undergoing maintenance hemodialysis, which may contribute to vascular and bone complications." | ( Carrero, JJ; Handu, D; Rozga, MR; St-Jules, DE, 2020) |
| "Hyperphosphatemia is a primary cause of CKD-related VC." | ( Chen, W; Guo, C; Pan, H; Peng, D; Wang, P, 2021) |
| "Hyperphosphatemia is associated with cardiovascular morbidity and mortality in patients receiving maintenance dialysis." | ( Chertow, GM; Pergola, PE; Rosenbaum, DP; Yang, Y, 2021) |
| "Hyperphosphatemia is associated with subclinical atheromatosis in chronic kidney disease." | ( Hénaut, L; Massy, ZA, 2021) |
| "Hyperphosphatemia is a common complication in patients on maintenance hemodialysis." | ( Li, P; Lian, R; Yin, J; Zheng, J, 2021) |
| "Hyperphosphatemia is a common complication as chronic kidney disease (CKD) progresses and most patients undergoing dialysis are prescribed oral phosphate binder therapy to control serum phosphate concentrations." | ( Ketteler, M; Sprague, SM, 2021) |
| "As hyperphosphatemia is associated with numerous adverse outcomes, including increased cardiovascular mortality, reduction in phosphorus concentrations is a guideline-recommended, established clinical practice." | ( Jacobs, JW; Rosenbaum, D; Sprague, SM; Yee, J, 2021) |
| "Hyperphosphatemia is a common feature in patients with chronic kidney disease (CKD), especially in those with end-stage renal disease (ESRD)." | ( Barbuto, S; Cianciolo, G; Ciceri, P; Cozzolino, M; Galassi, A; Iacovella, F; La Manna, G, 2022) |
| "Hyperphosphatemia is a common complication in dialysis-dependent patients with chronic kidney disease." | ( Coyne, DW; Kalantar-Zadeh, K; Ramos, R; Sprague, SM; Vervloet, M, 2022) |
| "Hyperphosphatemia is an inevitable complication for patients undergoing dialysis, as is the resulting need for treatment with phosphate binders." | ( Ito, H; Ogata, H; Takeshima, A, 2022) |
| "Hyperphosphatemia is often due to impaired kidney function and linked to vascular disease, hypertension and left ventricular hypertrophy." | ( Haffner, D; Leifheit-Nestler, M; Richter, B; Vogt, I, 2022) |
| "Hyperphosphatemia is almost universal in well-nourished patients with ESKD treated with dialysis due to an imbalance between dietary intake and phosphate removal via residual kidney function and dialysis." | ( Czikk, D; Farfan-Ruiz, AC; Leidecker, J; McCormick, B; Ramsay, T; Wilson, K; Zimmerman, D, 2021) |
| "Hyperphosphatemia is common in patients on peritoneal dialysis (PD)." | ( Andrews, ES; Kendrick, J; Perez, L; Ramirez-Renteria, L; Reddin, R; Teitelbaum, I; Wilson, G; You, Z, 2022) |
| "Hyperphosphatemia is a risk factor for cardiovascular outcomes in patients with chronic kidney disease." | ( Emoto, M; Fukumoto, S; Imanishi, Y; Mori, K; Morioka, T; Nagata, Y; Nakatani, S; Okute, Y; Shimomura, N; Shoji, T; Tsujimoto, Y; Uedono, H, 2023) |
| "Hyperphosphatemia is a secondary disorder of chronic kidney disease that causes vascular calcifications and bone-mineral disorders." | ( Anand, A; Aoyagi, H, 2023) |
| "Hyperphosphatemia is a common complication in advanced chronic kidney disease and contributes to cardiovascular morbidity and mortality." | ( Calabrese, V; Calderone, M; Casuscelli, C; Cernaro, V; Gembillo, G; Lo Re, C; Longhitano, E; Santoro, D, 2023) |
| "Hyperphosphatemia is associated with cardiovascular morbidity and mortality in adults with chronic kidney disease (CKD)." | ( Ai, X; Chen, X; Dong, H; Feng, J; Huang, B; Huang, X; Li, J; Li, L; Li, X; Li, Y; Luo, H; Xiao, H; Xue, G; You, S; Zhang, Y, 2023) |
| "BACKGROUND Hyperphosphatemia is a complication of chronic renal failure (CRF) due to reduction in the glomerular filtration rate." | ( Chang, X; Li, M; Shang, S; Xu, W; Yu, M; Zhou, Q, 2023) |